jilibet super ace

jilibet super ace -- First Half Revenue of $85.7 million , increase 1.5% year-over-year -- -- First Half GMV of $107.3 million , down 7.0% year-over-year -- SHANGHAI , Dec. 20, 2024 /PRNewswire/ -- Jowell Global Ltd. ("Jowell" or the "Company") (NASDAQ: JWEL), one of the leading cosmetics, health and nutritional supplements, and household products e-commerce platforms in China , today announced its unaudited financial results for the six months ended June 30, 2024 . First Half 2024 Financial and Operational Highlights and June 30, 2023. stores or store-in-shop (an integrated store), selling products they purchased through Jowell's online platform LHH Mall under their retailer accounts, which provides them with major discounts. Total Revenues Total revenues for the first half 2024 were $85.7 million , representing an increase of 1.5% from $84.4 million in the same period of 2023. Our weighted average unit price was $5.16 per unit for the first half of 2024, which represented an increase of 4.2% as compared to $4.95 per unit for the same period of 2023. Our health and nutritional supplements revenue for the first half of 2024 increased by about $11.1 million , or 182.1%, as compared to the same period of 2023. The increase in health and nutritional supplements revenue was mainly due to the increase in sales of premium brand health and nutritional supplements. We have stepped up our promotions on these items during the Chinese New Year holidays in the first half of 2024 in an attempt to offer more promotional discounts in response to the overall market downturn. Operating loss was $4.0 million for the first half of 2024, compared with the operating loss of $6.6 million in the same period of 2023. The decrease in operating loss for the first half of 2024 was mainly due the decrease of marketing expenses, as well as reduction of operating expenses as discussed above. Net Loss Net loss was $3.8 million , a decrease of 47.1% compared with net loss of $7.1 million in the same period of 2023, which was mainly due the factors mentioned above. Loss per Share The Company computes earnings (loss) per share ("EPS") in accordance with ASC 260, "Earnings per Share" ("ASC 260"). Each of the Company's Preferred Share has voting rights equal to two Ordinary Shares of the Company and each Preferred Share is convertible into one Ordinary Share at any time. Except for voting rights and conversion rights, the Ordinary Shares and the Preferred Shares rank pari passu with one another and have the same rights, preferences, privileges and restrictions. For the first half ended June 30, 2024 and 2023, respectively, the Company had no potential ordinary shares outstanding that could potentially dilute EPS in the future. Cash and Cash Equivalents For the first half of 2024, the Company reported a net loss of $3.8 million , a negative operating cash flow of $41,012 and an accumulated deficit of approximately $29.8 million . The Company's principal sources of liquidity are sales revenues, proceeds from a private placement and a registered direct offering. As of June 30, 2024 , the Company had cash and restricted cash of approximately $0.8 million , held by the variable interest entity (VIE) Shanghai Juhao Information Technology Co., Ltd. ("Shanghai Juhao") with banks and financial institutions inside China as the Company conducts its operations primarily through the consolidated VIE in China ; the Company's working capital as of June 30, 2024 was $13.4 million . Due to the uncertainty of the current market environment, management believes it is necessary to enhance the collection of its outstanding accounts receivable and other receivables, and to be cautious in terms of its operational decisions and project selections. As of October 31, 2024 , approximately $1.8 million , or 62%, of its accounts receivable balance as of June 30, 2024 were collected, and approximately $9.9 million , or 93%, of its advances to supplier balance as of June 30, 2024 were utilized. In addition, the Company's Form F-3 registration was declared effective on August 31, 2022 , and the Company may also seek equity financing from outside investors if necessary. Based on the latest business plan of the Company, Shanghai Juhao has reduced its promotion efforts and marketing expenditures since the second half of 2023, which reduced the cash used in operating activities. Management believes that the above-mentioned factors, including cash on hand of approximately $0.8 million , will provide sufficient liquidity for the Company to meet its future liquidity and capital requirements for at least the next twelve months. About Jowell Global Ltd . Jowell Global Ltd. (the "Company") is one of the leading cosmetics, health and nutritional supplements and household products e-commerce platforms in China . We offer our own brand products to customers and also sell and distribute health and nutritional supplements, cosmetic products and certain household products from other companies on our platform. In addition, we allow third parties to open their own stores on our platform for a service fee based upon sale revenues generated from their online stores and we provide them with our unique and valuable information about market needs, enabling them to better manage their sales effort, as well as an effective platform to promote their brands. The Company also sells its products through authorized retail stores all across China , which operate under the brand names of " Love Home Store " or "LHH Store" and "Best Choice Store". For more information, please visit http://ir.1juhao.com/ . Exchange Rate The Company's financial information is presented in U.S. dollars ("USD"). The functional currency of the Company is the Chinese Yuan, Renminbi ("RMB"), the currency of the PRC. Any transactions which are denominated in currencies other than RMB are translated into RMB at the exchange rate quoted by the People's Bank of China prevailing at the dates of the transactions, and exchange gains and losses are included in the statements of operations as foreign currency transaction gain or loss. The consolidated financial statements of the Company have been translated into U.S. dollars in accordance with ASC 830, "Foreign Currency Matters". This press release contains translations of certain RMB amounts into U.S. dollars ("USD" or "$") at specified rates solely for the convenience of the reader. The exchange rates in effect as of June 30, 2024 and December 31, 2023 were RMB1 for $0.1403 and $0.1412 , respectively. The average exchange rates for the six months ended June 30, 2024 and 2023 were RMB1 for $0.1407 and $0.1444 , respectively. Safe Harbor Statement This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; financial condition and results of operations; product and service demand and acceptance; reputation and brand; the impact of competition and pricing; changes in technology; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov . The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. For investor and media inquiries, please contact: Jowell Global Ltd. Ms. Jessie Zhao Email: [email protected] and outstanding at June 30, 2024 and December 31, 2023, respectively * outstanding at June 30, 2024 and December 31, 2023, respectively *

Even with access to blockbuster obesity drugs, some people don't lose weight

Standard Motor Products Releases 2,367 New Numbers in 2024Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

OLYMPIA — The Washington State Department of Agriculture has announced the successful eradication of the northern giant hornet, a five-year effort involving state officials, local landowners, beekeepers and citizen scientists. The group effort eliminated the invasive species from the state when it could have spread from the northwestern corner of the Evergreen State to the rest of the region. "It is a rare day when the humans actually get to win one against the insects," the Pest Program Manager at WSDA Sven-Erik Spichiger said. This invasive species, known for its devastating impact on bee populations, was first detected in Washington in December 2019. "None of this would be possible without everybody in Washington State and also from other parts of the country and other parts of the world that really helped make this possible," Spichiger said. He acknowledged the vital role played by landowners in Whatcom County, in particular. "The landowners generously allowed us access to their properties for trapping and eradication activities," he said. The cumulative efforts over the years led to the final trap being removed Dec. 5, with no additional hornets found since 2021. "I am absolutely honored to announce that eradication has been achieved and it's a significant victory for everybody who's involved," Spichiger said. The eradication effort was multifaceted and involved various stakeholders, according to the WSDA press release. Local beekeepers took the initiative to aid the WSDA by deploying spring traps to capture emerging queens, while citizen scientists participated in trapping and monitoring activities. "To me, this was absolutely huge because it allowed us to focus our resources in areas where we knew we had hornets," Spichiger said. The eradication initiative was initiated in response to public concerns after reports surfaced in 2013 of 42 fatalities resulting from hornet attacks in China, prompting discussions on potential responses to invasive species in the U.S. In 2016, a framework for responding to invasive hornets was developed, anticipating the need for rapid action in the event of an introduction. Spichiger explained how this groundwork supported their response strategy. "You know, we had a couple programs available that allowed citizen scientists to trap Asian giant hornets," Spichiger said, recognizing the important contributions from the community that led to success in the eradication process. The cooperative efforts came to fruition when WSDA successfully located and eradicated the first nest in October 2020, facilitated by advanced tracking technology borrowed from the United States Department of Agriculture. Nicole Russo, associate deputy administrator at USDA, expressed gratitude for the collaborative nature of the eradication. "A strong partnership between USDA's Animal and Plant Health Inspection Service and WSDA was an essential component of eradicating the Northern Giant Hornet from the United States," Russo said. "True to what we often see when partners come together to fight a destructive pest, a shared goal and determination brought promising results." As the battle against the hornet continued, community involvement became pivotal. Trappers worked in challenging conditions to check traps and check for hornet activity. During the three-year effort, multiple nests were detected and successfully eradicated. Efforts took place against the backdrop of the COVID-19 pandemic, which led to further complications. Despite these challenges, the team succeeded in tracking and eradicating multiple hornet nests, employing innovative methods such as radio telemetry technology. "The partnership with WSDA and APHIS was key to this remarkable accomplishment," Russo said, stating how the teams used tracking devices initially developed for other pest management efforts. Greg Halbrick, assistant director of the Plant Protection Division at WSDA, emphasized the importance of community support in their operation. "The amazing citizens of Whatcom County, including the beekeepers and citizen scientists that hung their traps, were extremely helpful," he said. Despite the announcement of eradication, Spichiger cautioned that vigilance must continue. "Although it is an absolutely significant victory, we won this battle. The battle will continue," he said, citing the ongoing risk of other invasive species, such as the yellow-legged hornet and the southern giant hornet recently discovered in Spain. The involvement of the community and multiple agencies proved critical in the success of the Asian giant hornet eradication project. "The fact of the matter is, if the entire community hadn't stood up and taken action, there is a real good chance that we would just all be living with northern giant hornet for years to come," Spichiger said. "It is a very difficult task to eradicate an insect once it has become well established. And these were established enough that they were actually attacking resources already." Get local news delivered to your inbox!BARCELONA, Spain--(BUSINESS WIRE)--Dec 19, 2024-- Wallbox N.V. (NYSE: WBX) (“Wallbox” or the “Company”), a leading provider of electric vehicle (“EV”) charging and energy management solutions worldwide, today announced that it received notice from the New York Stock Exchange (the “NYSE”) on November 21, 2024, that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual. This is because the average closing price of the Company’s Class A ordinary shares (the “Class A Shares”) was less than $1.00 over a consecutive 30 trading-day period. On December 2, 2024, the Company notified the NYSE that it intends to cure the share price deficiency and to regain compliance with the NYSE continued listing standards. The Company can regain compliance at any time within the six-month period following receipt of the NYSE notice if, on the last trading day of any calendar month during the cure period the Company has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. The Company intends to consider all available alternatives to cure the share price non-compliance to return to compliance with the NYSE continued listing standards. The notice has no immediate impact on the listing of the Class A Shares, which will continue to be listed and traded on the NYSE during this period, subject to the Company’s compliance with the other applicable NYSE listing standards. Wallbox emphasises that this notice does not affect its normal course of its business operations. The Company continues to execute its strategic priorities, which includes providing innovative EV charging and energy management solutions, focusing on maintaining business growth and delivering value to its core stakeholders. About Wallbox Wallbox is a global technology company, dedicated to changing the way the world uses energy. Wallbox creates advanced electric vehicle charging and energy management systems that redefine the relationship between users and the network. Wallbox goes beyond charging electric vehicles to give users the power to control their consumption, save money and live more sustainably. Wallbox offers a complete portfolio of charging and energy management solutions for residential, semi-public, and public use in more than 115 countries around the world. Founded in 2015 in Barcelona, where the company’s headquarters are located, Wallbox currently has offices across Europe, Asia, and America. For more information, visit www.wallbox.com Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release, other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements regarding Wallbox’s intention to consider alternatives to cure the NYSE continued listing requirement deficiency, Wallbox’s continued listing on the NYSE and expectations regarding business operations and future growth and delivering value to stakeholders. The words “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “focus,” “forecast,” “intend,” “likely,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “”target,” will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: Wallbox’s ability to regain compliance with the continued listing standards of the NYSE within the applicable cure period; as well as the other important factors discussed under the caption “Risk Factors” in Wallbox’s Annual Report on Form 20-F for the fiscal year ended December 31, 2023, as such factors may be updated from time to time in its other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investors Relations section of Wallbox’s website at investors.wallbox.com . Any such forward-looking statements represent management’s estimates as of the date of this press release. Any forward-looking statement that Wallbox makes in this press release speaks only as of the date of such statement. Except as required by law, Wallbox disclaims any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise. View source version on businesswire.com : https://www.businesswire.com/news/home/20241219135789/en/ CONTACT: Public Relations Albert Cabanes press@wallbox.comInvestor Relations Michael Wilhelm investors@wallbox.com KEYWORD: SPAIN EUROPE INDUSTRY KEYWORD: AUTOMOTIVE MANUFACTURING EV/ELECTRIC VEHICLES AUTOMOTIVE TECHNOLOGY MANUFACTURING SEMICONDUCTOR OTHER ENERGY OTHER TECHNOLOGY ALTERNATIVE ENERGY ENERGY ENGINEERING SOURCE: Wallbox Copyright Business Wire 2024. PUB: 12/19/2024 05:00 PM/DISC: 12/19/2024 05:00 PM http://www.businesswire.com/news/home/20241219135789/enWayfair CEO Niraj Shah sells $1.27 million in stockEven with access to blockbuster obesity drugs, some people don't lose weight

Hong Kong Innovation & Invention Spotlights Over 40 Local Innovations at Entrepreneur Day 2024From conflict to collaboration: Big tech repositions under Trump

ExpressVPN Black Friday deal: Get up to 61 percent off a 30-month plan

NEW YORK (AP) — An early rebound for U.S. stocks on Thursday petered out by the end of the day, leaving indexes close to flat. The S&P 500 edged down by 0.1% following Wednesday’s tumble of 2.9% when the Federal Reserve said it may deliver fewer cuts to interest rates next year than earlier thought. The index had been up as much as 1.1% in the morning. The Dow Jones Industrial Average rose 15 points, or less than 0.1%, following Wednesday’s drop of 1,123 points, while the Nasdaq composite slipped 0.1%. This week’s struggles have taken some of the enthusiasm out of the market, which critics had been warning was overly buoyant and would need everything to go correctly for it to justify its high prices. But indexes remain near their records , and the S&P 500 is still on track for one of its best years of the millennium with a gain of 23%. Traders are now expecting the Federal Reserve to deliver just one or maybe two cuts to interest rates next year, according to data from CME Group. Some are even betting on none. A month ago, the majority saw at least two cuts in 2025 as a safe bet. Wall Street loves lower interest rates because they give the economy a boost and goose prices for investments, but they can also provide fuel for inflation. Micron Technology was one of the heaviest weights on the S&P 500 Thursday. It fell 16.2% despite reporting stronger profit for the latest quarter than expected. The computer memory company’s revenue fell short of Wall Street’s forecasts, and CEO Sanjay Mehrotra said it expects demand from consumers to remain weaker in the near term. It gave a forecast for revenue in the current quarter that fell well short of what analysts were thinking. Lamb Weston, which makes French fries and other potato products, dropped 20.1% after falling short of analysts’ expectations for profit and revenue in the latest quarter. It also cut its financial targets for the fiscal year, saying demand for frozen potatoes is continuing to soften, particularly outside North America. The company replaced its chief executive. Such losses helped overshadow a 14.7% jump for Darden Restaurants, the company behind Olive Garden and other chains. It delivered profit for the latest quarter that edged past analysts’ expectations. The operator of LongHorn Steakhouses also gave a forecast for revenue for this fiscal year that topped analysts’. Accenture rose 7.1% after the professional services company likewise topped expectations for profit in the latest quarter. CEO Julie Sweet said it saw growth around the world, and the company raised its forecast for revenue this fiscal year. Amazon shares added 1.3%, even as workers at seven of its facilities went on strike Thursday in the middle of the online retail giant’s busiest time of the year. Amazon says it doesn’t expect an impact on its operations during what the workers’ union calls the largest strike against the company in U.S. history. In the bond market, yields were mixed a day after shooting higher on expectations that the Fed would deliver fewer cuts to rates in 2025. Reports on the U.S. economy came in mixed. One showed the overall economy grew at a 3.1% annualized rate during the summer, faster than earlier thought. The economy has remained remarkably resilient even though the Fed held its main interest rate at a two-decade high for a while before beginning to cut them in September. A separate report showed fewer U.S. workers applied for unemployment benefits last week, an indication that the job market also remains solid. But a third report said manufacturing in the mid-Atlantic region is unexpectedly contracting again despite economists’ expectations for growth. The yield on the 10-year Treasury rose to 4.57% from 4.52% late Wednesday and from less than 4.20% earlier this month. But the two-year yield, which more closely tracks expectations for action by the Fed in the near term, eased back to 4.31% from 4.35%. The rise in longer-term yields has put pressure on the housing market by keeping mortgage rates higher. Homebuilder Lennar fell 5.2% after reporting weaker profit and revenue for the latest quarter than analysts expected. CEO Stuart Miller said that “the housing market that appeared to be improving as the Fed cut short-term interest rates, proved to be far more challenging as mortgage rates rose” through the quarter. “Even while demand remained strong, and the chronic supply shortage continued to drive the market, our results were driven by affordability limitations from higher interest rates,” he said. A report on Thursday may have offered some encouragement for the housing industry. It showed a pickup in sales of previously occupied homes. All told, the S&P 500 slipped 5.08 points to 5,867.08. The Dow Jones Industrial Average added 15.37 to 42,342.24, and the Nasdaq composite lost 19.92 to 19,372.77. In stock markets abroad, London’s FTSE 100 fell 1.1% after the Bank of England paused its cuts to rates and kept its main interest rate unchanged on Thursday. The move comes as inflation there moved further above the central bank’s 2% target rate, while the British economy is flatlining at best. The Bank of Japan also kept its benchmark interest rate unchanged, and Tokyo’s Nikkei 225 fell 0.7%. Indexes likewise sank across much of the rest of Asia and Europe. AP Business Writers Matt Ott and Elaine Kurtenbach contributed.

-- First Half Revenue of $85.7 million , increase 1.5% year-over-year -- -- First Half GMV of $107.3 million , down 7.0% year-over-year -- SHANGHAI , Dec. 19, 2024 /PRNewswire/ -- Jowell Global Ltd. ("Jowell" or the "Company") (NASDAQ: JWEL), one of the leading cosmetics, health and nutritional supplements, and household products e-commerce platforms in China , today announced its unaudited financial results for the six months ended June 30, 2024 . First Half 2024 Financial and Operational Highlights [1] "Total VIP members" refers to the total number of members registered on Jowell's platform as of June 30, 2024 and June 30, 2023. [2] "LHH stores" refers to the brand name of "Love Home Store". Authorized retailers may operate as independent stores or store-in-shop (an integrated store), selling products they purchased through Jowell's online platform LHH Mall under their retailer accounts, which provides them with major discounts. First Half 2024 Financial Results Total Revenues Total revenues for the first half 2024 were $85.7 million , representing an increase of 1.5% from $84.4 million in the same period of 2023. Our weighted average unit price was $5.16 per unit for the first half of 2024, which represented an increase of 4.2% as compared to $4.95 per unit for the same period of 2023. Our health and nutritional supplements revenue for the first half of 2024 increased by about $11.1 million , or 182.1%, as compared to the same period of 2023. The increase in health and nutritional supplements revenue was mainly due to the increase in sales of premium brand health and nutritional supplements. We have stepped up our promotions on these items during the Chinese New Year holidays in the first half of 2024 in an attempt to offer more promotional discounts in response to the overall market downturn. First Half Ended June 30 % 2024 2023 change Revenues (in thousands, except for percentages) US$ US$ YoY* Product sales • Cosmetic products 19,768.5 29,495.5 (33.0 %) • Health and nutritional supplements 17,190.7 6,094.2 182.1 % • Household products 48,438.7 48,473.1 (0.1 %) • Others 286.4 343.4 (16.6 %) Total 85,684.3 84,406.2 1.5 % * YOY—year over year Total cost and operating expenses were $89.6 million in the first half of 2024, a decrease of 1.5% from $91.0 million in the same period of 2023. Operating Loss Operating loss was $4.0 million for the first half of 2024, compared with the operating loss of $6.6 million in the same period of 2023. The decrease in operating loss for the first half of 2024 was mainly due the decrease of marketing expenses, as well as reduction of operating expenses as discussed above. Net Loss Net loss was $3.8 million , a decrease of 47.1% compared with net loss of $7.1 million in the same period of 2023, which was mainly due the factors mentioned above. Loss per Share The Company computes earnings (loss) per share ("EPS") in accordance with ASC 260, "Earnings per Share" ("ASC 260"). Each of the Company's Preferred Share has voting rights equal to two Ordinary Shares of the Company and each Preferred Share is convertible into one Ordinary Share at any time. Except for voting rights and conversion rights, the Ordinary Shares and the Preferred Shares rank pari passu with one another and have the same rights, preferences, privileges and restrictions. For the first half ended June 30, 2024 and 2023, respectively, the Company had no potential ordinary shares outstanding that could potentially dilute EPS in the future. Cash and Cash Equivalents For the first half of 2024, the Company reported a net loss of $3.8 million , a negative operating cash flow of $41,012 and an accumulated deficit of approximately $29.8 million . The Company's principal sources of liquidity are sales revenues, proceeds from a private placement and a registered direct offering. As of June 30, 2024 , the Company had cash and restricted cash of approximately $0.8 million , held by the variable interest entity (VIE) Shanghai Juhao Information Technology Co., Ltd. ("Shanghai Juhao") with banks and financial institutions inside China as the Company conducts its operations primarily through the consolidated VIE in China ; the Company's working capital as of June 30, 2024 was $13.4 million . Due to the uncertainty of the current market environment, management believes it is necessary to enhance the collection of its outstanding accounts receivable and other receivables, and to be cautious in terms of its operational decisions and project selections. As of October 31, 2024 , approximately $1.8 million , or 62%, of its accounts receivable balance as of June 30, 2024 were collected, and approximately $9.9 million , or 93%, of its advances to supplier balance as of June 30, 2024 were utilized. In addition, the Company's Form F-3 registration was declared effective on August 31, 2022 , and the Company may also seek equity financing from outside investors if necessary. Based on the latest business plan of the Company, Shanghai Juhao has reduced its promotion efforts and marketing expenditures since the second half of 2023, which reduced the cash used in operating activities. Management believes that the above-mentioned factors, including cash on hand of approximately $0.8 million , will provide sufficient liquidity for the Company to meet its future liquidity and capital requirements for at least the next twelve months. About Jowell Global Ltd . Jowell Global Ltd. (the "Company") is one of the leading cosmetics, health and nutritional supplements and household products e-commerce platforms in China . We offer our own brand products to customers and also sell and distribute health and nutritional supplements, cosmetic products and certain household products from other companies on our platform. In addition, we allow third parties to open their own stores on our platform for a service fee based upon sale revenues generated from their online stores and we provide them with our unique and valuable information about market needs, enabling them to better manage their sales effort, as well as an effective platform to promote their brands. The Company also sells its products through authorized retail stores all across China , which operate under the brand names of " Love Home Store " or "LHH Store" and "Best Choice Store". For more information, please visit http://ir.1juhao.com/ . Exchange Rate The Company's financial information is presented in U.S. dollars ("USD"). The functional currency of the Company is the Chinese Yuan, Renminbi ("RMB"), the currency of the PRC. Any transactions which are denominated in currencies other than RMB are translated into RMB at the exchange rate quoted by the People's Bank of China prevailing at the dates of the transactions, and exchange gains and losses are included in the statements of operations as foreign currency transaction gain or loss. The consolidated financial statements of the Company have been translated into U.S. dollars in accordance with ASC 830, "Foreign Currency Matters". This press release contains translations of certain RMB amounts into U.S. dollars ("USD" or "$") at specified rates solely for the convenience of the reader. The exchange rates in effect as of June 30, 2024 and December 31, 2023 were RMB1 for $0.1403 and $0.1412 , respectively. The average exchange rates for the six months ended June 30, 2024 and 2023 were RMB1 for $0.1407 and $0.1444 , respectively. Safe Harbor Statement This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; financial condition and results of operations; product and service demand and acceptance; reputation and brand; the impact of competition and pricing; changes in technology; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov . The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. For investor and media inquiries, please contact: Jowell Global Ltd. Ms. Jessie Zhao Email: IR@1juhao.com Jowell Global Ltd. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2024 2023 (Unaudited) ASSETS Current Assets: Cash $ 805,344 $ 1,250,281 Accounts receivable, net 2,344,481 2,401,056 Accounts receivable - related parties - 47,040 Advance to suppliers 10,050,688 3,506,432 Advance to suppliers - related parties 12,493,792 9,874,545 Inventories 4,508,515 8,198,402 Prepaid expenses and other current assets 1,075,591 1,384,758 Total current assets 31,278,411 26,662,514 Long-term investment 3,709,340 3,888,377 Property and equipment, net 845,579 681,942 Intangible assets, net 532,810 634,655 Right of use lease assets, net 1,506,729 2,019,300 Other non-current asset 638,723 895,775 Deferred tax assets 512,175 515,364 Total Assets $ 39,023,767 $ 35,297,927 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Short-term loan $ 210,473 $ 423,567 Accounts payable 2,791,515 3,765,230 Accounts payable - related parties 280,530 194,818 Deferred revenue 11,691,812 2,309,957 Deferred revenue - related parties 40,000 47,059 Current portion of operating lease liabilities 1,475,947 942,989 Accrued expenses and other liabilities 975,072 782,048 Due to related parties 414,585 528,472 Taxes payable 1,487 58,233 Total current liabilities 17,881,421 9,052,373 Non-current portion of operating lease liabilities - 1,032,235 Total liabilities 17,881,421 10,084,608 Commitments and contingencies Equity Common stock, $0.0016 par value, 450,000,000 shares authorized, 2,170,475 issued and outstanding at June 30, 2024 and December 31, 2023, respectively * 3,473 3,473 Preferred stock, $0.0016 par value, 50,000,000 shares authorized, 46,875 issued and outstanding at June 30, 2024 and December 31, 2023, respectively * 75 75 Additional paid-in capital 52,687,182 52,687,182 Statutory reserves 394,541 394,541 Accumulated deficit (29,768,863) (26,039,567) Accumulated other comprehensive loss (2,153,720) (1,843,970) Total Jowell Glob

Wild first season in expanded Big 12 comes down to final weekendINDIANAPOLIS (WISH) — James Dean, the Hollywood icon who captured the world’s attention with his rebellious charm, is often remembered for his roles in classics like “Rebel Without a Cause” and “East of Eden.” But as author Jason Colavito reveals in his new book “Jimmy: The Secret Life of James Dean,” there’s much more to the story of the star from Marion, Indiana. Colavito’s book uncovers the hidden complexities of Dean’s life, particularly his struggles with his sexuality and how it shaped both his personal and public persona. Dean, who rose to fame in the 1950s, was a queer man navigating a time when such an identity was not only socially unacceptable, but illegal in many places across the U.S. “James Dean was a queer man, and his relationship with his own sexuality was troubled and complex. This really shaped the characters he portrayed on screen and the persona he created in the public eye,” Colavito said in an interview on News 8’s Daybreak. One of the most striking elements of Colavito’s work is the revelation that Dean’s sexuality was kept under wraps through blackmail and financial settlements, a tactic that ultimately impacted his career. In the 1950s LGBTQ individuals faced immense social and legal pressures, and for someone like Dean, the stakes were even higher. “In the 1950s, it was very difficult to be a queer person. It was against the law in many places, and there was both official oppression and a great deal of social condemnation. For someone like James Dean, it forced him to hide his true self,” Colavito said. Dean’s rebelliousness, his iconic ‘misunderstood’ image, and his intense on-screen performances were, according to Colavito, a product of this internal struggle. “All of that came from his experience as a queer person trying to navigate a world that didn’t accept him. His surliness, his misunderstood nature—those traits come from the pressures of living in a society where you couldn’t fully be yourself,” Colavito said. One of the major revelations in the book is the previously hidden relationship between James Dean and Rogers Brackett, a wealthy executive who allegedly blackmailed Dean in exchange for money. Colavito had access to a rare collection of documents, including business and financial papers related to Dean, which revealed the financial settlement Dean agreed to in order to keep the relationship secret and protect his burgeoning film career. “Dean reluctantly paid Brackett in exchange for his silence, all so that Dean could pursue his film career without scandal,” Colavito shared. “Brackett had hoped to use the money for an opera project, and Dean, on the brink of stardom, was forced into this agreement to avoid derailing his rise to fame.” The book not only paints a more human portrait of Dean, but also challenges the way the public has viewed the actor for decades. According to Colavito, the legacy of James Dean deserves more than the glossy, larger-than-life image built by Hollywood. Instead, we should look at the real man behind the myth. “I think the key takeaway from this book is understanding James Dean as a human being, not just as an icon or a movie star. He was a real person, facing real challenges in a world that didn’t accept him. That’s what makes his story even more compelling,” Colavito said. For Colavito, his work aims to offer a more complete understanding of the man behind the famous image— a story that resonates today as many of the same pressures and policies that Dean faced are making a comeback in today’s political climate. Colavito’s book “ Jimmy: The Secret Life of James Dean ” is on sale now.

Survey: Industries investing the most in employee mental wellbeingA new neutrino detector in China aims to spot mysterious ghost particles lurking around us

Wild first season in expanded Big 12 comes down to final weekend

( MENAFN - market Press Release) December 19, 2024 6:10 am - The global Electric Vehicle (EV) Market is on a trajectory of substantial expansion, propelled by environmental concerns, and rapid technological advancements. BIS Research, is closely monitoring these industry trends and key developments. Market Overview: The Electric Vehicle (EV) Market has experienced significant growth in recent years. In 2023, global electric car sales reached approximately 14 million units, a 35% increase from 2022, bringing the total number of electric cars on the road to around 40 million. In the European Union, battery electric vehicles (BEVs) accounted for 14.6% of new car registrations in 2023, continuing the upward trend in EV adoption. In the first half of 2024, global EV sales exceeded 7 million units, representing 17% of new light-duty vehicle sales. Projections indicate that global electric light-duty vehicle sales are set to reach 40% by 2030 and almost 55% by 2035, based on current policy settings. Regional Insights: Asia-Pacific: The Asia-Pacific EV fast-charging system market was valued at $7.13 billion in 2023 and is expected to reach $24.81 billion by 2033, with a compound annual growth rate (CAGR) of 13.28% during the forecast period. Europe: The Europe EV fast-charging system market was valued at $941.2 million in 2023 and is projected to reach $6,546.1 million by 2033, exhibiting a CAGR of 21.40% over the same period. Market Driving Factors: Environmental Concerns: The shift towards EVs is largely driven by the need to reduce greenhouse gas emissions and combat climate change. Government Regulation: Policies such as the Inflation Reduction Act (IRA) of 2022 in the United States are accelerating EV adoption by providing incentives and setting stringent emission standards. Technological Advancements: Continuous improvements in battery technology, charging infrastructure, and vehicle performance are making EVs more accessible and appealing to consumers. Challenges and Considerations: Despite the positive outlook, challenges such as the need for equitable access to EVs, the development of comprehensive charging infrastructure, and geopolitical tensions affecting supply chains remain. Addressing these issues is crucial for sustained growth in the EV market. About BIS Research: BIS Research is a global leader in providing actionable market intelligence on emerging technologies and trends, helping businesses make informed decisions in a rapidly evolving market environment. For more information, visit the website. MENAFN19122024003520003262ID1109014732 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.Even with access to blockbuster obesity drugs, some people don't lose weight

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Evolv Technologies Holdings, Inc. EVLV . Shareholders who purchased shares of EVLV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/evolv-technologies-holdings-inc-loss-submission-form-2/?id=113434&from=3 CLASS PERIOD: August 19, 2022 to October 30, 2024 ALLEGATIONS: According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that: Company's financial statements prepared for the periods between Q2 2022 through Q2 2024 contained material misstatements relating to improper revenue recognition and other reported metrics that are a function of revenue. In truth, Evolv's sales, including sales to one of its largest channel partners, were subject to extra-contractual terms and conditions not shared with the Company's accounting personnel, distorting the Company's reported revenue and other metrics that are a function of revenue during the Class Period. What's more, far from the Company's touted "growing momentum" and "continued traction" with channel partners, the Company's personnel was engaged in misconduct concerning sales to one of the Company's largest channel partners. DEADLINE: December 31, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/evolv-technologies-holdings-inc-loss-submission-form-2/?id=113434&from=3 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of EVLV during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is December 31, 2024. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: dg@securitiesclasslaw.com Phone: (646) 453-8903 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.AP Business SummaryBrief at 6:15 p.m. EST

Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Even with access to blockbuster obesity drugs, some people don't lose weight

CEO killer suspect: golden boy who soured on US health system